Teleflex announced today that Chair, President and CEO Liam Kelly is departing the company, effective immediately.

The Teleflex veteran has left the company without a permanent successor. Teleflex has made Stuart Randle, a board member, ...

Teleflex said the decision to move on from Kelly, who had been CEO since January 2018 and chairman since May 2022, is part of its shift to a more focused, higher-growth organization with the planned ...

Stuart Randle Appointed Interim President and CEOBoard Initiates Search for Permanent CEODr. Stephen Klasko Appointed Chairman of the ...

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device ...

Choose Philadelphia Business Journal as a preferred news source to see more of our reporting on Google.

Teleflex shares fell after the medical technology company said it was parting ways with its chief executive officer, and cut its outlook for the year. The stock was down 13% to $110.36 in late morning ...

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Teleflex on January 7 and set a price target of $135.00. The company’s shares closed yesterday at $126.53.

Teleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026. The company’s urology, acute care, and OEM businesses will be grouped under Teleflex ...

Teleflex is selling its acute care, interventional urology, and original equipment manufacturer (OEM) businesses in two separate deals totalling over $2bn as part of the company’s broader portfolio ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...